Compare GSK plc (GSK) vs Sea Limited (SE) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Sea Limited (SE) trades at $107.47, down 1.67% on the day, with a bullish technical outlook supported by moving averages and strong cash flow growth. Revenue surged to $22.94 billion in 2025, with net income reaching $1.58 billion, though recent earnings misses in Q3 and Q4 2025 temper momentum. Analyst sentiment remains optimistic with a $131 consensus price target, but insider selling and high valuation ratios pose caution.

The stock offers growth potential from expanding Southeast Asian digital services, but risks include competitive pressures and earnings volatility. With a P/E of 43.84, valuation is steep relative to peers, requiring sustained execution to justify upside. Investors should weigh robust fundamentals against near-term headwinds from insider transactions and macroeconomic uncertainty.